A detailed history of Charles Schwab Investment Management Inc transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,651,754 shares of RXRX stock, worth $10.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,651,754
Previous 1,213,012 36.17%
Holding current value
$10.2 Million
Previous $12.1 Million 2.44%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$7.35 - $10.05 $3.22 Million - $4.41 Million
438,742 Added 36.17%
1,651,754 $12.4 Million
Q1 2024

May 08, 2024

BUY
$9.13 - $15.52 $202,046 - $343,457
22,130 Added 1.86%
1,213,012 $12.1 Million
Q4 2023

Feb 06, 2024

BUY
$5.09 - $10.79 $167,542 - $355,163
32,916 Added 2.84%
1,190,882 $11.7 Million
Q3 2023

Nov 08, 2023

BUY
$6.59 - $15.86 $1.04 Million - $2.49 Million
157,189 Added 15.71%
1,157,966 $8.86 Million
Q2 2023

Aug 09, 2023

BUY
$4.56 - $9.94 $76,781 - $167,369
16,838 Added 1.71%
1,000,777 $7.48 Million
Q1 2023

May 11, 2023

SELL
$6.42 - $9.64 $4,763 - $7,152
-742 Reduced 0.08%
983,939 $6.56 Million
Q4 2022

Feb 13, 2023

BUY
$7.16 - $12.7 $574,067 - $1.02 Million
80,177 Added 8.86%
984,681 $7.59 Million
Q3 2022

Nov 14, 2022

BUY
$7.83 - $13.6 $3.73 Million - $6.48 Million
476,162 Added 111.16%
904,504 $9.62 Million
Q2 2022

Aug 15, 2022

BUY
$5.04 - $9.26 $278,097 - $510,948
55,178 Added 14.79%
428,342 $3.49 Million
Q1 2022

May 13, 2022

SELL
$6.16 - $18.03 $25,102 - $73,472
-4,075 Reduced 1.08%
373,164 $2.67 Million
Q4 2021

Feb 11, 2022

BUY
$16.14 - $21.86 $3.14 Million - $4.25 Million
194,467 Added 106.4%
377,239 $6.46 Million
Q3 2021

Nov 16, 2021

BUY
$19.03 - $41.33 $340,465 - $739,435
17,891 Added 10.85%
182,772 $4.21 Million
Q2 2021

Aug 16, 2021

BUY
$18.0 - $37.42 $2.97 Million - $6.17 Million
164,881 New
164,881 $6.02 Million

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.11B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.